Clinical trial · Observational
Recurrence Risk Evaluation by 21-gene Detection
Postoperative Recurrence Risk Evaluation of Hormone Receptor Positive, Her-2 Negative Breast Cancer by Using Different 21-gene Detection Kits (REBCK)
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Breast cancer patients with early breast cancer were enrolled according to the inclusion criteria. Baseline characteristics were recorded from medical record system. Recurrence score were obtained by 21-gene detection kits from different biological companies. Relationship between recurrence score and the prognosis was explored. Meanwhile, the investigators analyzed the consistency of the results obtained from various 21-gene test kits and immunohistochemistry detection.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Relationship and Consistency Analysis | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| recurrence risk evaluation | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- correlation analysis
- timeFrame
- Janyary 1, 2019-December 31, 2019
- description
- x2 value and P value of chi-square test
Secondary outcomes (1)
- measure
- consistency analysis
- timeFrame
- Janyary 1, 2019-December 31, 2019
- description
- kappa value, P value of consistency analysis
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: 1. breast cancer in stage I-III, tumor size\>0.5cm 2. lymph nodes negative 3. hormone receptor positive （ER+/PR+,ER+/PR-,ER-/PR+） 4. HER2 negative（IHC 0 or +， FISH negative） 5. receive endocrine therapy only 6. enough FFPE samples within 10 years（3\~6 10μm ） 7. patients with integrated medical records Exclusion Criteria: 1. Tumor cells \<5% 2. Isolated RNA\<500ng
References
Publications (0)
Data not yet available